- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00449033
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) (NEXUS)
April 3, 2015 updated by: Bayer
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
During follow-up, it was determined that there was one additional patient on placebo that was still receiving treatment as of 06 APR 2010 and therefore 10 patients' data are reported in the current CSR addendum, 6 in the sorafenib + GC group and 4 in the placebo + GC group, and as before all in the ITT (non-squamous) population.
Study Type
Interventional
Enrollment (Actual)
904
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Innsbruck, Austria, 6020
-
Linz, Austria, 4010
-
Wien, Austria, 1130
-
Wien, Austria, 1140
-
-
-
-
-
Brasschaat, Belgium, 2930
-
Bruxelles - Brussel, Belgium, 1200
-
Edegem, Belgium, 2650
-
Leuven, Belgium, 3000
-
Liege, Belgium, 4000
-
Namur, Belgium, 5000
-
-
-
-
-
Rio de Janeiro, Brazil, 20231 050
-
-
Bahia
-
Salvador, Bahia, Brazil, 40050410
-
Salvador, Bahia, Brazil, 40170-070
-
Salvador, Bahia, Brazil, 41820 021
-
-
Distrito Federal
-
Brasília, Distrito Federal, Brazil, 70840 901
-
-
Goiás
-
Goiania, Goiás, Brazil, 74605-070
-
Goiânia, Goiás, Brazil, 74075040
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30110-090
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90610-000
-
Porto Alegre, Rio Grande do Sul, Brazil, 90050 170
-
-
Sao Paulo
-
Jaú, Sao Paulo, Brazil, 17210-120
-
Santo Andre, Sao Paulo, Brazil, 09090-780
-
Santo André, Sao Paulo, Brazil, 09060-870
-
Sorocaba, Sao Paulo, Brazil, 18030-510
-
São Paulo, Sao Paulo, Brazil, 01221020
-
São Paulo, Sao Paulo, Brazil, 01331020
-
São Paulo, Sao Paulo, Brazil, 05403-010
-
São Paulo, Sao Paulo, Brazil, 05651-901
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1A1
-
-
-
-
-
Beijing, China, 100021
-
Shanghai, China, 200433
-
Shanghai, China, 200030
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
-
-
Hubei
-
Wuhan, Hubei, China, 430030
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
-
Hangzhou, Zhejiang, China, 310022
-
-
-
-
-
Nicosia, Cyprus, 2006
-
-
-
-
-
HUS, Finland, 00029
-
Preitilä, Finland, 21540
-
Tampere, Finland, FIN-33521
-
-
-
-
-
Bayonne, France, 64100
-
Grenoble, France, 38043
-
Grenoble, France, 38100
-
Hyeres, France, 83400
-
Le Mans Cedex 2, France, 72015
-
Marseille, France, 13275
-
Nantes, France, 44805
-
Nimes Cedex 2, France, 30907
-
Paris Cedex 15, France, 75908
-
Perpignan, France, 66000
-
Pierre Benite, France, 69495
-
Strasbourg, France, 67901
-
Tours, France, 37044
-
-
-
-
-
Hamburg, Germany, 21075
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany, 69126
-
Karlsruhe, Baden-Württemberg, Germany, 76137
-
Löwenstein, Baden-Württemberg, Germany, 74245
-
-
Bayern
-
Gauting, Bayern, Germany, 82131
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60431
-
Hofheim, Hessen, Germany, 65719
-
-
Nordrhein-Westfalen
-
Essen, Nordrhein-Westfalen, Germany, 45122
-
Köln, Nordrhein-Westfalen, Germany, 51109
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04207
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Germany, 22927
-
-
Thüringen
-
Bad Berka, Thüringen, Germany, 99437
-
-
-
-
-
Athens, Greece, 11527
-
-
Creta
-
Heraklion, Creta, Greece, 711 10
-
-
-
-
-
Budapest, Hungary, 1125
-
Budapest, Hungary, 1121
-
Deszk, Hungary, 6772
-
Matrahaza, Hungary, 3233
-
Szekesfehervar, Hungary, 8000
-
Torokbalint, Hungary, 2045
-
-
-
-
-
Ashkelon, Israel, 7830604
-
Holon, Israel, 58100
-
Kfar Saba, Israel, 4428164
-
Rehovot, Israel, 7610001
-
Tel Hashomer, Israel, 5262000
-
-
-
-
-
Bologna, Italy, 40138
-
Catania, Italy, 95122
-
Firenze, Italy, 50134
-
Livorno, Italy, 57124
-
Milano, Italy, 20132
-
Roma, Italy, 00152
-
Sassari, Italy, 07100
-
Venezia, Italy, 30122
-
Verona, Italy, 37134
-
-
Milano
-
Rozzano, Milano, Italy, 20089
-
-
Monza-Brianza
-
Monza, Monza-Brianza, Italy, 20052
-
-
Pordenone
-
Aviano, Pordenone, Italy, 33081
-
-
-
-
Distrito Federal
-
México, Distrito Federal, Mexico, 14080
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44280
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, 64460
-
-
-
-
-
Den Bosch, Netherlands, 5211 RW
-
Ede, Netherlands, 6716 RP
-
Harderwijk, Netherlands, 3844 DG
-
Heerlen, Netherlands, 6419 PC
-
Nieuwegein, Netherlands, 3435 CM
-
-
-
-
-
A Coruña, Spain, 15006
-
Barcelona, Spain, 08025
-
Madrid, Spain, 28040
-
Madrid, Spain, 28041
-
Málaga, Spain, 29010
-
Sevilla, Spain, 41013
-
Valencia, Spain, 46014
-
Valencia, Spain, 46010
-
Valencia, Spain, 46015
-
-
Barcelona
-
Terrassa, Barcelona, Spain, 08227
-
-
Bilbao
-
Cruces/Barakaldo, Bilbao, Spain, 48903
-
-
-
-
-
Bern, Switzerland, 3010
-
-
Basel-Stadt
-
Basel, Basel-Stadt, Switzerland, 4031
-
-
Genève
-
Genéve, Genève, Switzerland, 1205
-
-
-
-
-
Birmingham, United Kingdom, B15 2TH
-
London, United Kingdom, SE1 9RT
-
London, United Kingdom, SW3 6JJ
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
-
-
Grampian
-
Aberdeen, Grampian, United Kingdom, AB25 2ZN
-
-
Leicestershire
-
Leicester, Leicestershire, United Kingdom, LE1 5WW
-
-
Surrey
-
Sutton, Surrey, United Kingdom, SM2 5PT
-
-
West Midlands
-
Wolverhampton, West Midlands, United Kingdom, WV10 0QP
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age > 18 years old
- Stage IIIB (with cytologically confirmed malignant pleural or pericardial effusion) or Stage IV histological or cytological confirmation of NSCLC of non-squamous cell carcinoma subtype. (thoracentesis or pericardiocentesis is not necessary if a biopsy of the original tumor is available to confirm diagnosis of NSCLC).
- Patients with at least one measurable lesion. Lesions must be measured by CT-scan or MRI (Magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST, see Appendix 10.3)
- Life expectancy of at least 12 weeks
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:
- Hemoglobin >/= 9.0 g/dl (>/= 5.6 mmol/l)
- Absolute neutrophil count (ANC) >/= 1,500/mm3
- Platelet count >/= 100,000/µl
- Total bilirubin </= 1.5 x upper limit of normal
- Alanine transaminase (ALT) and Aspartate transaminase (AST) </= 2.5 x upper limit of normal (</= 5 x upper limit of normal for patients with liver involvement of their cancer)
- Alkaline Phosphatase </= 4 x upper limit of normal
- PT-INR (Prothrombin Time - International Normalized Ratio) (international normalized ratio of PT) /PTT (Partial Thromboplastin Time) < 1.5 x upper limit of normal
- Serum Creatinine </= 1.5 times the upper limit of normal and Serum Creatinine Clearance >/= 70ml/min
- Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to performing any study specific procedures.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Exclusion Criteria:
Excluded medical conditions:
- Cardiac disease: Congestive heart failure > class II NYHA (New York Heart Association). Patients must not have unstable angina (anginal symptoms at rest) or active coronary artery disease (CAD), or myocardial infarction within the past 6 months
- Cardiac arrhythmias requiring anti-arrhythmic therapy
- Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.
- History of HIV (Human immunodeficiency virus) infection or chronic hepatitis B or C
- Active clinically serious infections (> grade 2 NCI-CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 3.0)
- Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- Known brain metastasis. Patients with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis.
- History of organ allograft
- Patients with evidence or history of bleeding diathesis or coagulopathy
- Patients undergoing renal dialysis
- Cancer other than NSCLC within 5 years prior to start of study treatment EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors [Ta (Noninvasive tumor), Tis (Carcinoma in situ) & T1 (Tumor invades lamina propria)]
- Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.
- Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months
- Pulmonary hemorrhage/bleeding event > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug
- Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug
- Serious, non-healing wound, ulcer, or bone fracture
- Uncorrected dehydration
- Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- Known or suspected allergy to the investigational agent or any agent given in association with this trial
- Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- Patients unable to swallow oral medications
- Any malabsorption condition
- Patients with a hearing impairment (FOR GERMANY ONLY)
- NSCLC patients with squamous cell carcinoma diagnosis documented either by cytology or biopsy.
Excluded therapies and medications, previous and concomitant:
- Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents, experimental therapy, adjuvant, or neo-adjuvant therapy for NSCLC
- Concomitant use of nephrotoxic drugs, ototoxic drugs, anticonvulsant, anti-gout treatment
- Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section)
- Radiotherapy during study or within 4 weeks of start of study drug. (Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section) (FOR FRANCE ONLY)
- Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug (bronchoscopy is allowed)
- Granulocyte colony stimulating factor (GCSF) or Granulocyte macrophage colony stimulating factor (GMCSF), within 3 weeks of study entry (these growth factors may be used during the study thereafter).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sorafenib (Nexavar, BAY43-9006) + GC
Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with sorafenib.
Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: sorafenib 2 tablets (200 mg) taken orally (po) twice daily (bid).
If the patient had radiological evidence of stable disease (SD) or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which sorafenib was administered 400 mg bid until criteria for withdrawal were met.
|
Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
Chemotherapy component; Gemcitabine 1250 mg/m^2 IV
Chemotherapy component; Cisplatin 75 mg/m^2 IV
|
PLACEBO_COMPARATOR: Placebo + GC
Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with placebo.
Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: placebo 2 tablets po bid.
If the patient had radiological evidence of SD or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which 2 placebo tablets were administered bid until criteria for withdrawal were met.
|
Chemotherapy component; Gemcitabine 1250 mg/m^2 IV
Chemotherapy component; Cisplatin 75 mg/m^2 IV
Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS) in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death of any cause whichever came first
|
Overall survival (OS) was defined as the time from date of randomization to death due to any cause.
Patients still alive at the time of analysis were censored at their last date of last contact.
|
from randomization of the first patient until 38 months or date of death of any cause whichever came first
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS in the ITT (Both Squamous and Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death of any cause whichever came first
|
OS was defined as the time from date of randomization to death due to any cause.
Patients still alive at the time of analysis were censored at their last date of last contact.
|
from randomization of the first patient until 38 months or date of death of any cause whichever came first
|
OS in the ITT (Squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death of any cause whichever came first
|
OS was defined as the time from date of randomization to death due to any cause.
Patients still alive at the time of analysis were censored at their last date of last contact.
|
from randomization of the first patient until 38 months or date of death of any cause whichever came first
|
Progression-free Survival (PFS) in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
PFS was defined as the time from date of randomization to disease progression (radiological or clinical, whichever was earlier, based on Investigator-assessment using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0) or death due to any cause, whichever occured first.
Patients without progression or death at the time of analysis were censored at their last date of tumor evaluation.
Disease progression: increase in the sum of tumor lesion sizes or new lesions.
|
from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
Time to Progression (TTP) in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
TTP was defined as the time from date of randomization to disease progression (radiological or clinical, whichever was earlier, based on Investigator-assessment using RECIST version 1.0).
Patients without progression at the time of analysis or death before progression were censored at their last date of tumor evaluation.
Disease progression: increase in the sum of tumor lesion sizes or new lesions.
|
from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
Percentage of Participants With Different Tumor Response in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
Tumor response (= Best Overall Response) of a patient was defined as the best tumor response (confirmed Complete Response (CR: disappearance of tumor lesions), confirmed Partial Response (PR: a decrease of at least 30% in the sum of tumor lesion sizes), Stable Disease (SD: steady state of disease), or Progressive Disease (PD: an increase in the sum of tumor lesions sizes or new lesions)) observed during trial period assessed according to the RECIST criteria (version 1.0) based on Investigator-assessment.
|
from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
Disease Control (DC) in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
DC was defined as the total number of patients whose best response was not PD according to RECIST (version 1.0) by Investigator-assessment (= total number of CR + total number of PR + total number of SD; CR or PR had to be maintained for at least 28 days from the first demonstration of that rating, SD had to be documented at least once more than 6 weeks from baseline).
PD: an increase in the sum of tumor lesions sizes or new lesions.
|
from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
Duration of Response in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
Duration of response was defined as the time from date of first documented objective response of PR or CR, whichever was noted earlier, to date of disease progression or death (if death occurred before progression was documented).
Patients without disease progression at the time of analysis or death before progression were censored at the last date of tumor evaluation.
Disease progression: increase in the sum of tumor lesion sizes or new lesions.
|
from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
Duration of Stable Disease (SD) in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
Duration of SD was defined as the time from date of randomization to date that disease progression (radiological or clinical, whichever was earlier) was first documented.
Patients without disease progression at the time of analysis or death before progression were censored at the date of their last tumor assessment.(Disease
progression: increase in the sum of tumor lesion sizes or new lesions.)
Duration of stable disease was only evaluated in patients failing to achieve a best response of CR or PR.
|
from randomization of the first patient until 38 months or date of death or progression whichever came first, assessed until discontinuation every 6 weeks up to 9 months and then every 12 weeks
|
Time to Response (TTR) in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months or date of death of any cause whichever came first
|
TTR for patients who achieved a best response (CR or PR) was defined as the time from date of randomization to the earliest date that response was first documented.
|
from randomization of the first patient until 38 months or date of death of any cause whichever came first
|
Functional Assessment of Cancer Treatment-Lung (FACT-L) Scores in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months
|
The FACT-L measures health related quality of life (HRQOL) and composes of five domains: the four domains (physical well being, emotional well being, social well being, functional well being) from the Functional Assessment of Cancer Treatment-General scale (FACT-G) and the lung cancer subscale (LCS).
The FACT-L total score ranges from 0 to 136, higher scores represent better HRQOL.
|
from randomization of the first patient until 38 months
|
Lung Cancer Subscale (LCS) Scores in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient to 38 months later or death whatever occurs first.
|
LCS is a subscale of FACT-L measuring lung cancer specific symptoms.
The LCS scores range from 0 to 28, higher scores represent fewer lung cancer symptoms.
|
from randomization of the first patient to 38 months later or death whatever occurs first.
|
Time to Symptomatic Deterioration (TSD) in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient to 38 months later or death whatever occurs first
|
TSD is defined as the time from randomization to the date of symptomatic deterioration (≥3 point decline in the LCS score that is maintained for at least 2 consecutive cycles) or death if death occurs before these 2 consecutive cycles are completed.
|
from randomization of the first patient to 38 months later or death whatever occurs first
|
Euro Quality of Life - 5D (EQ-5D) Index Scores in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months later or death whatever occurs first
|
The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression.
These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 to 1 when the United Kingdom (UK) weights are applied (0=death, 1=perfect health).
Higher index scores represent better health states.
|
from randomization of the first patient until 38 months later or death whatever occurs first
|
EQ-5D Visual Analog Scale (VAS) Scores in the ITT (Non-squamous) Population
Time Frame: from randomization of the first patient until 38 months later or death whatever occurs first
|
The EQ-5D also contains a visual analog scale (EQ-VAS), which records the respondent's self-rated health status on a vertical graduated visual analog scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
|
from randomization of the first patient until 38 months later or death whatever occurs first
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Primary Completion (ACTUAL)
April 1, 2010
Study Completion (ACTUAL)
June 1, 2011
Study Registration Dates
First Submitted
March 16, 2007
First Submitted That Met QC Criteria
March 16, 2007
First Posted (ESTIMATE)
March 19, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
April 23, 2015
Last Update Submitted That Met QC Criteria
April 3, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protein Kinase Inhibitors
- Gemcitabine
- Cisplatin
- Sorafenib
Other Study ID Numbers
- 12006
- 2006-002688-26 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Sorafenib (Nexavar, BAY43-9006)
-
BayerCompletedHepatocellular CarcinomaTaiwan
-
BayerTerminatedCarcinoma, Renal CellItaly, Spain, France, Austria, Poland, United Kingdom, Ireland
-
University of FloridaCompleted
-
BayerCompletedCarcinoma, Renal Cell | Carcinoma, HepatocellularKorea, Republic of
-
BayerCompletedCarcinoma, HepatocellularJapan
-
BayerCompletedCarcinoma, Renal CellBelgium, Italy, Spain, Germany, France, Netherlands, Switzerland, Poland, Sweden, United Kingdom, Denmark
-
BayerTerminated
-
BayerCompleted